{"created":"2025-05-21T21:47:43.349131+00:00","id":2067427,"links":{},"metadata":{"_buckets":{"deposit":"f041755f-0a0b-4221-a524-23bf4a880e5b"},"_deposit":{"id":"2067427","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2067427"},"status":"published"},"_oai":{"id":"oai:teikyo-u.repo.nii.ac.jp:02067427","sets":["1726879085919:1741828256493"]},"author_link":[],"item_1551264308487":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―","subitem_title_language":"en"}]},"item_1551264340087":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"familyNames":[{"familyName":"Kitaoka"}],"givenNames":[{"givenName":"Hiroaki"}]},{"familyNames":[{"familyName":"Ieda"}],"givenNames":[{"givenName":"Masaki"}]},{"familyNames":[{"familyName":"Ebato"}],"givenNames":[{"givenName":"Mio"}]},{"familyNames":[{"familyName":"kouzuma","familyNameLang":"en"},{"familyName":"上妻","familyNameLang":"ja"}],"givenNames":[{"givenName":"ken","givenNameLang":"en"},{"givenName":"謙","givenNameLang":"ja"}]},{"familyNames":[{"familyName":"Takayama"}],"givenNames":[{"givenName":"Morimasa"}]},{"familyNames":[{"familyName":"Tanno"}],"givenNames":[{"givenName":"Kaoru"}]},{"familyNames":[{"familyName":"Komiyama"}],"givenNames":[{"givenName":"Nobuyuki"}]},{"familyNames":[{"familyName":"Sakata"}],"givenNames":[{"givenName":"Yasushi"}]},{"familyNames":[{"familyName":"Maekawa"}],"givenNames":[{"givenName":"Yuichiro"}]},{"familyNames":[{"familyName":"Minami"}],"givenNames":[{"givenName":"Yuichiro"}]},{"familyNames":[{"familyName":"Ogimoto"}],"givenNames":[{"givenName":"Akiyoshi"}]},{"familyNames":[{"familyName":"Takaya"}],"givenNames":[{"givenName":"Tomofumi"}]},{"familyNames":[{"familyName":"Yasuda"}],"givenNames":[{"givenName":"Satoshi"}]},{"familyNames":[{"familyName":"Amiya"}],"givenNames":[{"givenName":"Eisuke"}]},{"familyNames":[{"familyName":"Furukawa"}],"givenNames":[{"givenName":"Yutaka"}]},{"familyNames":[{"familyName":"Watanabe"}],"givenNames":[{"givenName":"Tetsuya"}]},{"familyNames":[{"familyName":"Hiraya"}],"givenNames":[{"givenName":"Daigo"}]},{"familyNames":[{"familyName":"Miyagoshi"}],"givenNames":[{"givenName":"Hidetaka"}]},{"familyNames":[{"familyName":"Kinoshita"}],"givenNames":[{"givenName":"Gen"}]},{"familyNames":[{"familyName":"Reedy"}],"givenNames":[{"givenName":"Alison"}]},{"familyNames":[{"familyName":"Hegde"}],"givenNames":[{"givenName":"Sheila M."}]},{"familyNames":[{"familyName":"Florea"}],"givenNames":[{"givenName":"Victoria"}]},{"familyNames":[{"familyName":"Izumi"}],"givenNames":[{"givenName":"Chisato"}]}]},"item_1551264447183":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1551264822581":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"Efficacy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Hypertrophic cardiomyopathy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Mavacamten","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Safety","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cardiology and Cardiovascular Medicine","subitem_subject_language":"en","subitem_subject_scheme":"SciVal"},{"subitem_subject":"循環器および心血管医学","subitem_subject_language":"ja","subitem_subject_scheme":"SciVal"},{"subitem_subject":"SDG 3 - Good Health and Well-being","subitem_subject_language":"en","subitem_subject_scheme":"SDG"},{"subitem_subject":"SDG 3 - すべての人に健康と福祉を","subitem_subject_language":"ja","subitem_subject_scheme":"SDG"}]},"item_1551264846237":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"<p>Background: Mavacamten, a cardiac myosin inhibitor, significantly improved symptoms and cardiac function vs. placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in EXPLORER-HCM. However, the efficacy and safety profiles of mavacamten in Japanese patients are unclear. Methods and Results: HORIZON-HCM is a Phase 3 single-arm study in Japanese patients with symptomatic obstructive HCM. The mavacamten starting dose was 2.5 mg; individualized dose titration occurred in Weeks 6–20 based on Valsalva left ventricular outflow tract (LVOT) gradient and resting left ventricular ejection fraction (LVEF). Overall, 38 patients were treated; 36 completed the 30-week primary treatment analysis period. Clinically significant improvements in postexercise LVOT gradient were observed after 30 weeks of treatment (mean change from baseline −60.7 mmHg). Improvements in N-terminal pro B-type natriuretic peptide, New York Heart Association class, and Kansas City Cardiomyopathy Questionnaire-23 Clinical Summary Score were observed over 30 weeks, and mean LVEF was ≥74% at all visits. Treatment-emergent adverse events (TEAEs) and serious TEAEs were reported in 63.2% and 7.9% of patients, respectively; none resulted in treatment discontinuation. One patient experienced a transient asymptomatic reduction in LVEF to &lt;50%. No deaths occurred during the study. Conclusions: In Japanese patients with obstructive HCM, mavacamten was associated with similar improvements in LVOT gradients, cardiac biomarkers, and symptoms to those observed in EXPLORER-HCM. Treatment was well tolerated with no new safety concerns.</p>","subitem_description_language":"en"}]},"item_1551264974654":{"attribute_name":"Date","attribute_value_mlt":[{"subitem_date_issued_datetime":"2024-12-25","subitem_date_issued_type":"Issued"}]},"item_1551265002099":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"en"}]},"item_1551265032053":{"attribute_name":"item_1551265032053","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1551265227803":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"39505542","subitem_relation_type_select":"PubMed"}},{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"85214055822","subitem_relation_type_select":"QABO"}},{"subitem_relation_type":"isPartOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"1346-9843","subitem_relation_type_select":"ISSN"}}]},"item_1551265438256":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_source_title":"Circulation Journal"}]},"item_1551265463411":{"attribute_name":"巻","attribute_value_mlt":[{"subitem_volume":"89"}]},"item_1551265520160":{"attribute_name":"号","attribute_value_mlt":[{"subitem_issue":"1"}]},"item_1551265553273":{"attribute_name":"ページ数","attribute_value_mlt":[{"subitem_number_of_pages":"9"}]},"item_1551265569218":{"attribute_name":"開始ページ","attribute_value_mlt":[{"subitem_start_page":"130"},{"subitem_start_page":"138"}]},"item_title":"Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―","item_type_id":"12","owner":"1","path":["1741828256493"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2025-05-08"},"publish_date":"2025-05-08","publish_status":"0","recid":"2067427","relation_version_is_last":true,"system_identifier_doi":{"attribute_name":"Persistent Identifier(DOI)","attribute_value_mlt":[{"subitem_systemidt_identifier":"https://doi.org/10.1253/circj.CJ-24-0501","subitem_systemidt_identifier_type":"DOI"}]},"title":["Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2025-05-21T21:47:44.749579+00:00"}